Theravance Biopharma (TBPH) Assets Average (2014 - 2026)

Theravance Biopharma (TBPH) has reported Assets Average for 13 consecutive years, with $478.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 37.28% year-over-year to $478.9 million; the TTM figure through Mar 2026 stood at $478.9 million (up 37.28% YoY), while the FY2025 annual figure was $419.9 million, up 14.07% from the prior year.
• Assets Average improved to $478.9 million in Q1 2026 per TBPH's latest filing, from $450.5 million in the prior quarter.
• Across five years, Assets Average topped out at $685.4 million in Q4 2022 and bottomed at $348.9 million in Q1 2025.
• Historically, Assets Average has averaged $435.6 million across 5 years, with a median of $397.8 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average jumped 76.22% — and 2023, when it plunged 41.97%.
• Theravance Biopharma's Assets Average stood at $685.4 million in 2022, then sank by 41.97% to $397.8 million in 2023, then slipped by 10.72% to $355.1 million in 2024, then advanced by 26.86% to $450.5 million in 2025, then gained by 6.31% to $478.9 million in 2026.
• Business Quant data shows TBPH's Assets Average at $478.9 million in Q1 2026, $450.5 million in Q4 2025, and $420.7 million in Q3 2025.